English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary  The Canadian Hemophilia Assessment and Resource Management System ( CHARMS ) tracks factor concentrates ( FC ) from the sole suppliers, Canadian Blood Services ( CBS ) and Hema‐Quebec ( HQ ), to hospitals and to patients’ homes. Patients  FC  infusion data are entered into  CHARMS  at Canadian Hemophilia Treatment Centres ( HTC s) then exported to the national database (CentrePoint). From 2000 to 2009, 2260 registered haemophilia A or B patients received  FVIII  (1 009 097 765 IU) and  FIX  (272 406 859 IU). Over 91% of  FVIII  and over 84% of  FIX  was infused at home. Utilization of  FVIII  progressively increased; this was accounted for by an increase in the number of patients treated ( r  = 0.97;  P  <   0.001), there being a linear relationship between the increase in utilization and the increase in number of patients treated ( P  <   0.001). There was also a correlation with the annual amount used per patient ( r  =   0.95;  P  <   0.001). Utilization of  FIX  did not increase over time. The highest proportional utilization of both  FVIII  and  FIX  was for prophylaxis, and this proportion progressively increased being, in year 10 (2009), 77% and 66% for  FVIII  and  FIX  respectively. The proportion used for bleeding remained steady; in year 10 that proportion was 14% for  FVIII  and 26% for  FIX , the use per patient for bleeding decreasing. The  HTC ‐based  CHARMS  tracking system is essential, in Canada, for analysing indications for infusion, for predicting utilization and planning for future needs.

haemophilia

First analysis of 10‐year trends in national factor concentrates usage in haemophilia: data from  CHARMS , the Canadian Hemophilia Assessment and Resource Management System